Analysis of the trend of changes in the liver cancer burden attributed to drinking in China from 1990 to 2019_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Shanshan ^1,2 , HE Yujing ¹ , LI Chuyi ¹ , ZHENG Ying ¹ , YU Xiaohui ¹ , LI Bin ¹ ,  LU Lixia ¹

1. Department of Gastroenterology, 940 Hospital of the Joint Logistics Support Force of the People’s Liberation Army of China, Lanzhou 730050, P. R. China;
2. The First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou 730000, P. R. China;

Corresponding?author：

LU Lixia, Email: 584778162@qq.com

Keywords：

Drinking; Liver cancer; Disease burden; China

DOI：

10.7507/1672-2531.202309068

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the trend of changes in the burden of liver cancer diseases attributed to alcohol consumption in China from 1990 to 2019. Methods Data on liver cancer burden attributed to drinking in China from 1990 to 2019 were obtained from the global burden of disease 2019. Joinpoint regression model was used to analyze the temporal trend of disease burden, and age-period-cohort model was used to evaluate age, period, and cohort effects. Results From 1990 to 2019, the standardized incidence rate of liver cancer attributable to drinking among the total population, men and women showed a downward trend. The AAPC was ?2.52% (95%CI ?2.83% to ?2.21%), 3.26% (95%CI ?3.62% to ?2.89%) and ?2.24% (95%CI ?2.61% to ?1.86%), respectively; The standardized mortality rates showed a decreasing trend, with AAPC values of ?2.86% (95%CI ?3.46% to ?2.26%), ?3.48% (95%CI ?4.20% to ?2.76%), and ?2.67% (95%CI ?2.99% to ?2.34%), respectively; The standardized DALY rates showed a downward trend, with AAPC values of ?3.09% (95%CI ?3.65% to ?2.53%), ?2.92% (95%CI ?3.25% to ?2.58%), and ?3.77 (95%CI ?4.21% to ?3.31%), respectively. The trend changes were statistically significant (P<0.05). From 1990 to 2019, the overall risk of liver cancer incidence and death attributed to drinking in China, both in males and females, showed a trend of first increasing and then decreasing with age; As the period increased, both the overall population and the male population showed a downward trend, followed by an upward trend, while the female population remained relatively stable; The lower the risk of liver cancer incidence and death attributed to drinking as the queue progressed. Conclusion The standardized incidence rate, mortality and DALY rates of liver cancer attributable to drinking in China are generally declining, we should strengthen health education and early diagnosis and treatment for both male and elderly people to reduce the burden of liver cancer.

Citation： LIU Shanshan, HE Yujing, LI Chuyi, ZHENG Ying, YU Xiaohui, LI Bin, LU Lixia. Analysis of the trend of changes in the liver cancer burden attributed to drinking in China from 1990 to 2019. Chinese Journal of Evidence-Based Medicine, 2024, 24(7): 776-782. doi: 10.7507/1672-2531.202309068 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	Zheng RS, Zhang SW, Zeng HM. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent, 2022, 2: 1-9.
3.	Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol, 2018, 69(3): 718-735.
4.	Papadimitriou N, Markozannes G, Kanellopoulou A, et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun, 2021, 12(1): 4579.
5.	Maucort-Boulch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer, 2018, 142(12): 2471-2477.
6.	He F, Sha Y, Wang B. Relationship between alcohol consumption and the risks of liver cancer, esophageal cancer, and gastric cancer in China: meta-analysis based on case-control studies. Medicine (Baltimore), 2021, 100(33): e26982.
7.	GBD 2019 Viewpoint Collaborators. Five insights from the global burden of disease study 2019. Lancet, 2020, 396(10258): 1135-1159.
8.	GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet, 2020, 396(10258): 1223-1249.
9.	Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000, 19(3): 335-351.
10.	李輝章, 杜靈彬. Joinpoint回歸模型在腫瘤流行病學時間趨勢分析中的應用. 中華預防醫學雜志, 2020, 54(8): 908-912.
11.	Xu D, Hu J, Wang S, et al. Trends in the prevalence of hypertensive heart disease in china from 1990 to 2019: a joinpoint and age-period-cohort analysis. Front Public Health, 2022, 10: 833345.
12.	鄭榮壽, 陳萬青. 基于貝葉斯方法的年齡-時期-隊列預測模型的介紹. 中華預防醫學雜志, 2012, 46(7): 648-650.
13.	Rosenberg PS. A new age-period-cohort model for cancer surveillance research. Stat Methods Med Res, 2019, 28(10-11): 3363-3391.
14.	姬衛東. 年齡-時期-隊列模型在部分慢性傳染性疾病的應用. 烏魯木齊: 新疆醫科大學, 2021.
15.	劉俊生, 武勇杰, 原悅. 人口老齡化、公共支出與生態可持續. 經濟問題, 2023, (4): 37-44.
16.	王鵬舉. 1990-2019年我國肝癌發病與死亡趨勢及預測研究. 蘭州: 蘭州大學, 2021.
17.	Liu Z, Song C, Suo C, et al. Alcohol consumption and hepatocellular carcinoma: novel insights from a prospective cohort study and nonlinear Mendelian randomization analysis. BMC Med, 2022, 20(1): 413.
18.	Im PK, Millwood IY, Kartsonaki C, et al. Alcohol drinking and risks of total and site-specific cancers in China: a 10-year prospective study of 0.5 million adults. Int J Cancer, 2021, 149(3): 522-534.
19.	Zhang Y, Li ZY, Shen QM, et al. A prospective cohort study of cigarette smoking, alcohol drinking and liver cancer incidence in Chinese men. J Dig Dis, 2022, 23(8-9): 527-534.
20.	Park H, Shin SK, Joo I, et al. Systematic review with meta-analysis: low-level alcohol consumption and the risk of liver cancer. Gut Liver, 2020, 14(6): 792-807.
21.	曾紅梅, 蔡建強. 中國肝癌診治現狀再思考. 肝癌電子雜志, 2021, 8(2): 23-25.
22.	赫捷, 陳萬青, 沈洪兵, 等. 中國人群肝癌篩查指南(2022, 北京). 中國腫瘤, 2022, 31(8): 587-631.
23.	Cao M, Li H, Sun D, et al. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond), 2020, 40(5): 205-210.
24.	Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050. Int J Cancer, 2021, 148(5): 1051-1065.
25.	王世越, 董晨, 常楚迪, 等. 中國原發性肝癌基層篩查的機遇與挑戰. 中國全科醫學, 2023, 26(36): 4498-4504, 4520.
26.	馬恒敏, 李曉, 韓洪冰, 等. 2007—2021年山東省淮河流域癌癥早診早治項目篩查結果初步分析. 中國腫瘤, 2022, 31(10): 759-765.
27.	單天昊, 安瀾, 徐夢圓, 等. 2020年全球肝癌和膽囊癌發病死亡分析. 肝癌電子雜志, 2022, 9(4): 46-51.
28.	張戈, 付建成. 抗戰時期陜甘寧邊區的群眾醫療衛生政策及其實踐—以邊區疫病防治為中心的分析. 西北大學學報(哲學社會科學版), 2021, 51(3): 46-53.
29.	王秋童, 胡亞男, 楊曉瑩, 等. 中國4省農村地區肝癌預防知信行變化情況. 中國健康教育, 2023, 39(4): 298-304.
30.	姜潔, 錢姣, 朱立國, 等. 江蘇省2010年和2020年乙型肝炎血清流行病學特征分析. 中華疾病控制雜志, 2023, 27(2): 238-243.
31.	陳倩倩, 芮法娟, 倪文婧, 等. 原發性肝癌的流行病學及其危險因素研究進展. 中國全科醫學, 2024, 27(6): 637-642.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. Zheng RS, Zhang SW, Zeng HM. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent, 2022, 2: 1-9.
3. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol, 2018, 69(3): 718-735.
4. Papadimitriou N, Markozannes G, Kanellopoulou A, et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun, 2021, 12(1): 4579.
5. Maucort-Boulch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer, 2018, 142(12): 2471-2477.
6. He F, Sha Y, Wang B. Relationship between alcohol consumption and the risks of liver cancer, esophageal cancer, and gastric cancer in China: meta-analysis based on case-control studies. Medicine (Baltimore), 2021, 100(33): e26982.
7. GBD 2019 Viewpoint Collaborators. Five insights from the global burden of disease study 2019. Lancet, 2020, 396(10258): 1135-1159.
8. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet, 2020, 396(10258): 1223-1249.
9. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000, 19(3): 335-351.
10. 李輝章, 杜靈彬. Joinpoint回歸模型在腫瘤流行病學時間趨勢分析中的應用. 中華預防醫學雜志, 2020, 54(8): 908-912.
11. Xu D, Hu J, Wang S, et al. Trends in the prevalence of hypertensive heart disease in china from 1990 to 2019: a joinpoint and age-period-cohort analysis. Front Public Health, 2022, 10: 833345.
12. 鄭榮壽, 陳萬青. 基于貝葉斯方法的年齡-時期-隊列預測模型的介紹. 中華預防醫學雜志, 2012, 46(7): 648-650.
13. Rosenberg PS. A new age-period-cohort model for cancer surveillance research. Stat Methods Med Res, 2019, 28(10-11): 3363-3391.
14. 姬衛東. 年齡-時期-隊列模型在部分慢性傳染性疾病的應用. 烏魯木齊: 新疆醫科大學, 2021.
15. 劉俊生, 武勇杰, 原悅. 人口老齡化、公共支出與生態可持續. 經濟問題, 2023, (4): 37-44.
16. 王鵬舉. 1990-2019年我國肝癌發病與死亡趨勢及預測研究. 蘭州: 蘭州大學, 2021.
17. Liu Z, Song C, Suo C, et al. Alcohol consumption and hepatocellular carcinoma: novel insights from a prospective cohort study and nonlinear Mendelian randomization analysis. BMC Med, 2022, 20(1): 413.
18. Im PK, Millwood IY, Kartsonaki C, et al. Alcohol drinking and risks of total and site-specific cancers in China: a 10-year prospective study of 0.5 million adults. Int J Cancer, 2021, 149(3): 522-534.
19. Zhang Y, Li ZY, Shen QM, et al. A prospective cohort study of cigarette smoking, alcohol drinking and liver cancer incidence in Chinese men. J Dig Dis, 2022, 23(8-9): 527-534.
20. Park H, Shin SK, Joo I, et al. Systematic review with meta-analysis: low-level alcohol consumption and the risk of liver cancer. Gut Liver, 2020, 14(6): 792-807.
21. 曾紅梅, 蔡建強. 中國肝癌診治現狀再思考. 肝癌電子雜志, 2021, 8(2): 23-25.
22. 赫捷, 陳萬青, 沈洪兵, 等. 中國人群肝癌篩查指南(2022, 北京). 中國腫瘤, 2022, 31(8): 587-631.
23. Cao M, Li H, Sun D, et al. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond), 2020, 40(5): 205-210.
24. Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050. Int J Cancer, 2021, 148(5): 1051-1065.
25. 王世越, 董晨, 常楚迪, 等. 中國原發性肝癌基層篩查的機遇與挑戰. 中國全科醫學, 2023, 26(36): 4498-4504, 4520.
26. 馬恒敏, 李曉, 韓洪冰, 等. 2007—2021年山東省淮河流域癌癥早診早治項目篩查結果初步分析. 中國腫瘤, 2022, 31(10): 759-765.
27. 單天昊, 安瀾, 徐夢圓, 等. 2020年全球肝癌和膽囊癌發病死亡分析. 肝癌電子雜志, 2022, 9(4): 46-51.
28. 張戈, 付建成. 抗戰時期陜甘寧邊區的群眾醫療衛生政策及其實踐—以邊區疫病防治為中心的分析. 西北大學學報(哲學社會科學版), 2021, 51(3): 46-53.
29. 王秋童, 胡亞男, 楊曉瑩, 等. 中國4省農村地區肝癌預防知信行變化情況. 中國健康教育, 2023, 39(4): 298-304.
30. 姜潔, 錢姣, 朱立國, 等. 江蘇省2010年和2020年乙型肝炎血清流行病學特征分析. 中華疾病控制雜志, 2023, 27(2): 238-243.
31. 陳倩倩, 芮法娟, 倪文婧, 等. 原發性肝癌的流行病學及其危險因素研究進展. 中國全科醫學, 2024, 27(6): 637-642.

Chinese Journal of Evidence-Based Medicine

Analysis of the trend of changes in the liver cancer burden attributed to drinking in China from 1990 to 2019

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content